SCHEMBL4714540

SCHEMBL4714540

CCOC(=O)c1cc2ncccc2n1Cc1cccc(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOD2 Q9HC29 1/20 0.51
NOD1 Q9Y239 1/20 0.51
MAPT P10636 4/20 0.51
KMT2A Q03164 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
PTGDR2 Q9Y5Y4 1/20 0.50
ALDH1A1 P00352 4/20 0.49
F10 P00742 3/20 0.49
TDP1 Q9NUW8 3/20 0.49
KDM4E B2RXH2 3/20 0.49
MEN1 O00255 2/20 0.49
POLB P06746 2/20 0.49
HPGD P15428 2/20 0.49
LMNA P02545 1/20 0.49
MAPK1 P28482 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
TSHR P16473 1/20 0.49
ATM Q13315 1/20 0.49
ALOX5 P09917 1/20 0.48
CCR2 P41597 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4714196 0.90 MAPT (0.60) NOD2NOD1MAPTKMT2ASMN1; SMN2
SCHEMBL4713839 0.89 NOD2 (0.53) NOD2NOD1MAPTKMT2ASMN1; SMN2
SCHEMBL4715565 0.87 NOD2 (0.51) NOD2NOD1MAPTKMT2ASMN1; SMN2
SCHEMBL4716980 0.84 NOD2 (0.50) NOD2NOD1MAPTKMT2ASMN1; SMN2
SCHEMBL6307843 0.82 NOD2 (0.74) NOD2NOD1MAPTKMT2ASMN1; SMN2
SCHEMBL4653221 0.80 F10 (0.59) NOD2NOD1MAPTKMT2ASMN1; SMN2
SCHEMBL30489126 0.78 KDM4E (0.49) NOD2NOD1MAPTKMT2ASMN1; SMN2
SCHEMBL18322260 0.78 KDM4E (0.49) NOD2NOD1MAPTKMT2ASMN1; SMN2
SCHEMBL4717021 0.77 MAPT (0.50) NOD2NOD1MAPTKMT2ASMN1; SMN2
SCHEMBL6091573 0.77 NOD2 (0.56) NOD2NOD1MAPTKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed
EP-1549648-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS Celltech R & D Limited (GB) 2005-07-06 EP disclosed
WO-2004031188-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS CELLTECH R & D LIMITED (GB) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 NOD2 138/4885NOD1 312/4885MAPT 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.